



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20366-044US1	Application No. 10/530,000
		Applicant Kavanaugh, et al.	
		Filing Date March 31, 2005	Group Art Unit

**Information Disclosure Statement
by Applicant**
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US- 4,551,482	11-05-1985	Tschang, et al.			
	AB	US- 4,764,369	08-16-1988	Neurath, et al.			
	AC	US- 4,820,805	04-11-1989	Neurath, et al.			
	AD	US- 5,405,770	04-11-1995	McIntosh			
	AE	US- 5,490,840	02-13-1996	Uzgiris, et al.			
	AF	US- 5,510,103	04-23-1998	Yokoyama, et al.			
	AG	US- 5,651,991	07-29-1997	Sugiyama, et al.			
	AH	US- 5,688,931	11-18-1997	Nogusa, et al.			
	AI	US-5,108,619	04-21-1992	Wieseahn, et al.			
	AJ	US-5,418,130	05-23-1995	Platz, et al.			
	AK	US- 5,714,166	02-03-1998	Tomalia, et al.			
	AL	US- 5,750,383	05-12-1998	Blissard, et al.			
	AM	US- 5,786,387	07-28-1998	Watanabe, et al.			
	AN	US- 5,855,900	01-05-1999	Nobuhiko			
	AO	US-5,858,410	01-12-1999	Muller, et al.			
	AP	US- 5,922,356	07-13-1999	Koseki, et al.			
	AQ	US- 5,922,545	07-13-1999	Mattheakis, et al.			
	AR	US- 5,994,392	11-30-1999	Shashoua			
	AS	US-6,001,806	12-14-1999	Hilbert, et al.			
	AT	US- 8,106,866	08-22-2000	Ranney			
	AU	US-6,090,925	07-18-2000	Woiszwilllo, et al.			
	AV	US-6,120,787	09-19-2000	Gustafsson, et al.			
	AW	US-6,190,700	02-20-2001	Okada, et al.			
	AX	US- 8,194,192	02-27-2001	Ueno, et al.			
	AY	US-6,200,959	03-13-2001	Haynes, et al.			
	AZ	US-6,221,958	04-24-2001	Shalaby, et al.			
	AAA	US-6,238,704	05-29-2001	Suzuki, et al.			

Examiner Signature /Mary Mosher/	Date Considered 11/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20366-044US1	Application No. 10/530,000
		Applicant Kavanaugh, et al.	
		Filing Date March 31, 2005	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	US-6,238,705	05-29-2001	Liu, et al.			
	ACC	US-6,245,740	06-12-2001	Goldenberg, et al.			
	ADD	US- 6,248,514	06-19-2001	Hutchins, et al.			
	AEE	US-6,262,127	07-17-2001	Acemoglu, et al.			
	AFF	US-6,267,981	07-31-2001	Okamoto, et al.			
	AGG	US-6,287,587	09-11-2001	Shigeyuki, et al.			
	AHH	US-6,296,842	10-02-2001	Jaworowicz, et al.			
	AII	US-6,312,713	11-06-2001	Korol, et al.			
	AJJ	US-6,335,035	01-01-2002	Drizen, et al.			
	AKK	US- 6,379,958	04-30-2002	Vaughn, et al.			
	ALL	US-6,451,303	09-17-02	Whitehouse, et al.			
	AMM	US- 2002/0015945	02-07-2002	Polo, et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	ANN	WO 90/14837	12-13-90	WIPO				
	AOO	WO 92/19265	11-12-92	WIPO				
	APP	WO 93/13202	07-08-93	WIPO				
	AQQ	WO 98/50091	11-12-98	WIPO				
	ARR	WO 99/30739	06-24-99	WIPO			X (Abstract)	
	ASS	WO 00/38706	07-06-00	WIPO				
	ATT	WO 02/06305	01-24-02	WIPO			X (Abstract)	
	AUU	WO 03/24480	03-27-03	WIPO				
	AVV	WO 03/24481	03-27-03	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document

Examiner Signature /Mary Mosher/	Date Considered 11/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20366-044US1	Application No. 10/530,000
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kavanaugh, et al.	
		Filing Date March 31, 2005	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AWW	ABE, et al., <i>Journal of Immunology</i> (2003) 171:1133-1139.
	AXX	AUSUBEL (ed.), <i>Short Protocols in Molecular Biology</i> , 3 rd ed. (New York: Wiley, 1995).*
	AYY	BAGGIOLINI, et al., "Human Chemokines: An Update," <i>Annu Rev Immunol</i> (1997) 15:675-705.
	AZZ	BERKOW, et al., <i>The Merck Manual of Medical Information</i> , Home ed. (Merck Research Laboratories, Whitehouse Station, New Jersey, 1997).*
	AAAA	BODANSZKY, <i>Principles of Peptide Synthesis</i> , 2 nd rev. (Berlin: Springer-Verlag).*
	ABBB	BOYCE & BUCHER, "Baculovirus-mediated gene transfer into mammalian cells," <i>Proc Natl Acad Sci USA</i> (1996) 93:2348-52.
	ACCC	BRONTE, "Genetic Vaccination for the Active Immunotherapy of Cancer," <i>Curr Gene Ther</i> (2001) 1:53-100.
	ADDD	CARBONELL, et al., "Baculovirus-Mediated Expression of Bacterial Genes in Drosophila and Mammalian Cells," <i>J. Virol</i> (1985) 59:153-60.
	ABEE	CARBONELL & MILLER, "Baculovirus Interaction with Nontarget Organisms: A Virus-Borne Reporter Gene Is Not Expressed in two Mammalian Cell Lines," <i>Appl Environ Microbiol</i> (1987) 53:1412-7.
	AFFF	COTTEN, et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs) using the endosome-disruption activity of defective or chemically inactivated adenovirus particles," <i>Proc Natl Acad Sci USA</i> (1992) 89:6094-8.
	AGGG	DAVIS, et al., "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen," <i>J. Immunol</i> (1998) 160:870-876.
	AHHH	EBADI, <i>CRC Desk Reference of Clinical Pharmacology</i> (CRC Press, Boca Raton, Florida, 1998).*
	AIII	FEARON, "Seeking wisdom in innate immunity," <i>Nature</i> (1997) 388:323-324.
	AJJJ	FEARON & LOCKSLEY, "The Instructive Role of Innate Immunity in the Acquired Immune Response," <i>Science</i> (1996) 272:50-54.
	AKKK	FEHNIGER, TA., et al., "Interleukin-2 and interleukin-15: immunotherapy for cancer," <i>Cytokine Growth Factor Rev</i> (2002) 13:169-83.
	ALLL	FIELDS, B., et al., <i>Virology</i> , Vol. 1, 3 rd ed. (Philadelphia, PA: Lippincott-Rave Publishers, 1996).*
	AMMM	GERBER, et al., "Human Papillomavirus Virus-Like Particles are Efficient Oral Immunogens When Coadministered with Escherichia Coli Heat-Labile Enterotoxin Mutant R192G or CpG," <i>Journal of Virology</i> (2001) 75(10):4752-4760.
	ANNN	GLOVER & HAMES, "DNA Cloning: A Practical Approach," 2 nd ed. (Oxford/New York: IRL Press at Oxford University Press, 1995).*
	AOOO	GLUCK, et al., "New Technology Platforms in the Development of Vaccines for the Future," <i>Vaccine</i> (2002) 20:B10-B16.
	APPP	GOODMAN, et al., <i>Goodman & Gilman's the Pharmacological Basis of Therapeutics</i> , 9 th ed. (New York: McGraw-Hill Health Professions Division, 1996).*
	AQQQ	GRONER, et al., "Interaction of Autographa californica nuclear polyhedrosis virus with two nonpermissive cell lines," <i>Intervirology</i> (1984) 21:203-9.
	ARRR	GRONOWSKI, AM, et al., "Baculovirus stimulates antiviral effects in mammalian cells," <i>J. Virology</i> (Dec. 1999) 73(12): 9944-51.
	ASSS	HENZLER & KAISER, "Avoiding viral contamination in biotechnological and pharmaceutical processes," <i>Nat Biotechnol</i> (1998) 16:1077-79.
	ATTT	HOFMANN, C., et al., "Efficient gene transfer into human hepatocytes by baculovirus vectors," <i>Proc. Natl Acad Sci USA</i> (1995) 92:10099-103.
	AUUU	HOMEY, et al., "Chemokines: agents for the immunotherapy of cancer," <i>Nat Rev Immunol</i> (2002) 2:175-84.
	AVVV	HWANG, et al., "The solution structure of a psoralen cross-linked DNA duplex by NMR and relaxation matrix refinement," <i>Biochem Biophys Res Commun</i> (1996) 219:191-7.
	AWWW	JANEWAY, CA, Jr., <i>Approaching the Asymptote? Evolution and Revolution in Immunology</i> , <i>Cold Spring Harb Symp Quant Biol</i> (1989) 54:1-13.

Examiner Signature <i>/Mary Mosher/</i>	Date Considered 11/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20366-044US1	Application No. 10/530,000
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kavanaugh, et al.	
		Filing Date March 31, 2005	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AXXX	JIN, et al., "The LEF-4 Subunit of Baculovirus RNA Polymerase Has RNA 5'-Triphosphatase and ATPase Activities," <i>Journal of Virology</i> (1998) 72:10011-10019.
	AYYY	JUNG & LITTMAN, "Chemokine receptors in lymphoid organ homeostasis," <i>Curr Opin Immunol</i> (1999) 11:319-25.
	AZZZ	KATZUNG, Basic & Clinical Pharmacology, 8 th ed., (Lange Medical Books/McGraw-Hill Medical Pub. Division, New York, 2001). *
	AAAAA	KING & POSSEE, The Baculovirus Expression System: A Laboratory Manual (London: Chapman & Hall, 1992). *
	ABBBB	KOOL, M. & VLAK, JM, "The structural and functional organization of the Autographa californica nuclear polyhedrosis virus genome," <i>Arch Virol</i> 130:1-16.
	ACCCC	KRIEG, et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> (1995) 374:546.
	ADDDD	LENG, et al., "Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells," <i>Journal of Immunology</i> (2001) 5346-5355.
	AEEEE	MANOME, et al., "Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir," <i>Cancer Res</i> (1994) 54:5408-13.
	AFFFF	MAMOUNE A, et al. "Calpain-2 as a target for limiting prostate cancer invasion," <i>Cancer Res.</i> (2003) Aug 1. 63(15): 4632-40.
	AGGGG	MARX, G., et al., "Protecting fibrinogen with rutin during UVC irradiation for viral inactivation," <i>Photochem Photobiol</i> (1996) 63:541-6.
	AHHHH	MCINTOSH, AH, "Biological studies of a baculovirus in a mammalian cell line," <i>Intervirology</i> (1980) 13:331-41.
	AIIII	MCLACHLIN, JR, et al., "A baculovirus mutant defective in P10P, a protein which interacts with a virus-encoded protein kinase," <i>Virology</i> (1998) 246:379-391.
	AJJJJ	NIIKURA, et al., "Chimeric Recombinant Hepatitis E Virus-Like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes," <i>Virology</i> (2002) 293:273-280.
	AKKKK	PARMIANI, G. et al., "Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?" <i>J. Natl. Cancer Inst.</i> (2002) 94:805-18.
	ALLLL	PARTINGTON, S., et al., "Isolation of temperature sensitive mutants of Autographa californica nuclear polyhedrosis virus: phenotype characterization of baculovirus mutants defective in very late gene expression," <i>Virology</i> (1990) 175:91-102.
	AMMMM	PATHAK, M., et al. "Phytophotodermatitis," In Sunlight and Man, eds. Pathak, M. & Fitzpatrick, T. (Tokyo: University of Tokyo Press, 1974) 495-513.
	ANNNN	PEARSON, MN, et al., "P39, a major baculovirus structural protein: immunocytochemical characterization and genetic location," <i>Virology</i> (1988) 167:407-13.
	AOOOO	PINTO, et al., "Cellular Immune Responses to Human Papillomavirus (HPV)-16 L1 Healthy Volunteers Immunized with Recombinant HPV-16/L1 Virus-Like Particles," <i>Journal of Infectious Diseases</i> (2003) 188:327-338.
	APPPP	REMINGTON, et al., Remington's Pharmaceutical Sciences, 15 th ed. (Mack Pub. Co., Easton, PA, 1975). *
	AQQQQ	ROBBINS & ANGELL, "Neoplasia and Other Disturbances of Cell Growth", Basic Pathology, 2d Ed. (Philadelphia, Pennsylvania: W.B. Saunders Co., 1976), pp. 68-79.
	ARRRR	ROHMANN, GF, et al., "Baculovirus structural proteins," <i>J. Gen Virol</i> (1992) 73 (Pt. 4):743-61.
	ASSSS	ROMAGNANI, S., "Induction of Th1 and Th2 Responses: a key role for the 'natural' immune response?" <i>Immunol Today</i> (1992) 13:379-381.
	ATTTT	SALTZMAN, WM, "Polymeric implants for cancer chemotherapy," <i>Adv Drug Deliv Rev</i> , (1997) 26:209-30.
	AUUUU	SCHNEIDER, CH, et al., Peptides, 1992: Proceedings of the Twenty-Second European Peptide Symposium, September 13-19, 1992 Interlaken, Switzerland, Escom, Leiden.
	AVVVV	SCHREIBER, RD, et al., "Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity," <i>J. Immunol</i> (1985) 134:1609-18.
	AWWWW	SCHROEDER & LUBKE, The Peptides (New York: Academic Press, 1965). *
	AXXXX	SHIM BS, et al., "Anti-metastatic effects of fuzhengfangaitang on human fibrosarcoma cells HT1080," <i>Am. J. Chin Med</i> (2003) 31(2):235-46.

Examiner Signature /Mary Mosher/	Date Considered 11/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20366-044US1	Application No. 10/530,000
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kavanaugh, et al.	
		Filing Date March 31, 2005	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AYYYY	SILHAVY, TJ, et al., Experiments with Gene Fusions. (New York: Cold Spring Harbor Laboratory, Cold Spring Harbor, 1984).*
	AZZZZ	SPEIGHT, et al., Avery's Drug Treatment: A Guide to the Properties, Choice, Therapeutic Use and Economic Value of Drugs in Disease Management, 4th ed. (Adis International, Auckland/Philadelphia, PA).*
	AAAAAA	ST. CLAIR, N., et al., "Cross-linked protein crystals for vaccine delivery," <i>Applied Biol. Sci.</i> (1998) 96:9489-9474.
	ABBBBB	SUMMERS, MD, et al., "Baculovirus structural polypeptides," <i>Virology</i> (1978) 84:390-402.
	ACCCCC	THIEM, SM, et al., "Identification, sequence and transcriptional mapping of the major capsid protein gene of the baculovirus <i>Autographa californica</i> nuclear polyhedrosis virus," <i>J. Virol.</i> (1989) 63:2008-18.
	ADDDDD	TJIA, ST, et al., " <i>Autographa californica</i> nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells," <i>Virology</i> (1983) 125:107-17.
	AEEEEEE	TWEETEN, K., et al., "Characterization of an extremely basic protein derived from granulosis virus nucleocapsids," <i>J. Virol</i> (1980) 33:866-876.
	AFFFFF	VIALARD, JE, et al., "The 1,629-nucleotide open reading frame located downstream of the <i>Autographa californica</i> nuclear polyhedrosis virus polyhedron gene encodes a nucleocapsid-associated phosphoprotein," <i>Virol</i> (1993) 67:5859-66.
	AGGGGG	VOLKMAN, L, et al., "In vitro survey of <i>Autographa californica</i> nuclear polyhedrosis virus interaction with nontarget vertebrate host cells," <i>Appl Environ Microbio</i> (1983) 45:1085-1093.
	AMHHHH	WILSON, ME, et al., "Location, transcription and sequence of a baculovirus gene encoding a small arginine-rich polypeptide," <i>J. Virol</i> (1987) 61:661-6.
	AIIIII	YANG, et al., "Overexpression of <i>KAI1</i> Suppresses <i>in Vitro</i> Invasiveness and <i>in Vitro</i> Metastasis in Breast Cancer Cells," <i>Cancer Res</i> (July 1 2001) 61: 5284-5288.
/MM/	AJJJJJ	International Search Report from International Application No. PCT/US2003/031320, published as WO 2004/030631 dated 8 Aug 2004.

Examiner Signature /Mary Mosher/	Date Considered 11/18/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	